- ESMO
ESMO 2024
Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatments
Donwload Press release (PDF)
Donwload the Poster (PDF) - Presentation
Transgene in a nutshell
Corporate Presentation
Universal Registration Document
